Figure 5. Three TRPs-related genes signatures could predict the efficacy of clinical standard-of-care chemotherapy. Chemo-resistant group is defined by progressive disease (PD), whereas chemo-sensitive tumors combine responding cases of partial response (PR), complete response (CR), or stable disease (SD) (A) SVM model to assess the signature’s efficacy for predicting chemotherapy. (B) ROC curve to verify the accuracy of the SVM model. (C) The difference of MCOLN1 gene expression between the chemoresistant group and chemosensitive group. (D) The difference of TRPM5 gene expression between the chemoresistance group and chemosensitivity group. (E) The difference of TRPV4 gene expression in dependency of the chemo resistance level of the tumor. (F) Association between TRPM5 expression and overall survival in the drug-resistant group of COAD patients. (G) Association between TRPM5 expression and progression-free interval in the drug-resistant group of COAD patients. (H) Correlation of TRPM5 gene expression and MDR1 gene expression.